HOPE II Study
Human Papillomavirus One-Dose-vaccine Prevention Efficacy among Women Living with HIV (HOPE II) Study
Study Rationale
The HOPE II Study aims to explore whether a single-dose HPV vaccine can effectively prevent persistent HPV infections in women living with HIV, particularly targeting HPV strains linked to cervical cancer. This study focuses on women who had previously received an HPV 16/18 vaccination before their HIV diagnosis.
Study Details
The study targets women aged 16 and older, living with HIV, and reporting one to five lifetime sexual partners. As a double-blind, randomized controlled study, HOPE-II evaluates the efficacy of immediate versus delayed administration of a single-dose HPV vaccine in preventing high-risk HPV types. The study will be conducted at three sites: Wits RHI in South Africa, Botswana Harvard Partnership (BHP) in Botswana, and Inshuti Mu Buzima in Rwanda, with a planned sample size of 750 participants.
Primary Objective
To assess the effectiveness of a single-dose nonavalent HPV vaccine in preventing persistent infections with HPV types 16, 18, 31, 33, 45, 52, and 58 in women living with HIV who had prior HPV 16/18 vaccination.
Secondary Objectives
- Evaluate the vaccine’s effectiveness in preventing persistent infections with HPV types 31, 33, 45, 52, and 58.
- Assess the safety and tolerability of the single-dose nonavalent HPV vaccine in women living with HIV.
Investigators
- Prof Sinead Delany-Moretlwe, Principal Investigator
Media Coverage
- Spotlight, 19 June 2024: HPV vaccination switching to single dose and private schools to get government supply
Interested in Participating
If you’re interested in participating in the HOPE II Study or would like more information, please reach out via:
- WhatsApp, SMS, or “Please Call Me” at 076 840 1106
Latest Update
October 2024
For More Information
For details about the HOPE II Study, please email rhicomms@wrhi.ac.za
Click here for additional information regarding the study.
